Mitsubishi Chemical buys Tanabe for $4.3B
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Mitsubishi Chemical Holdings |
Tanabe Seiyaku |
$4.3 billion buyout |
Mitsubishi Chemical Holdings is buying Tanabe Seiyaku for $4.3 billion in a deal that will double its drug sales. |
|
Schering-Plough |
Anacor Pharmaceuticals |
$625M licensing deal |
The deal is for Anacor's experimental fungal therapy. |
|
Cytyc Corporation |
Adeza Biomedical Corporation |
$452 acquisition |
Cytyc makes surgical and diagnostic products targeting women's health and cancer diagnostics, and Adeza manufactures and markets products for women's health. |
|
GlaxoSmithKline |
XenoPort |
$350M deal |
XenoPort is selling most of the worldwide rights to XP13512, a new version of the nerve drug gabapentin, to GlaxoSmithKline for $75 million up front and $275 million. |
|
Otsuka |
GW Pharmaceuticals |
$273M deal |
GW Pharmaceuticals and Japan's Otsuka signed a deal to develop and market GW's cannabis-based drug Sativex in the U.S. |
|
AstraZeneca |
Regeneron Pharmaceuticals |
$120 licensing deal |
AstraZeneca will use Regeneron Pharmaceuticals use its VelocImmune technology to discover therapeutic antibodies. |
|
Pfizer |
BioRexis Pharmaceutical |
Buyout |
BioRexis uses protein engineering technology in its work developing new therapies for diabetes. |